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ABSTRACT 
 
Background 
 
Carcinoma of the cervix is a common cancer among women in developing 
countries and with the rising HIV environment the burden of cervical cancer 
might be even greater, stretching the limited resources even further. This 
retrospective descriptive study evaluates the potential of the hypofractionated 
departmental protocol for stage 3b carcinoma of the cervix in terms of toxicity, 
local control, and compares toxicity for HIV negative and positive patients with a 
mean follow-up of one year. This study also compares the outcome for unilateral 
to bilateral pelvic sidewall fixed tumours. 
 
Methods and Materials 
 
Medical records of 104 sequential patients with stage 3b carcinoma of the cervix 
treated with departmental hypofractionated protocols between 2010/2011 were 
reviewed. The patients were only sequential after meeting the criterion of being 
local with a contact telephone number. Patients were treated with two-
dimensional standard pelvic portals of external beam radiation therapy of 2.5Gray 
daily to a total of 40Gray and intracavitary radiotherapy high dose rate of 9Gray 
weekly to a total of 18Gray. All cases were stratified by HIV status as being HIV 
positive or negative and by local disease spread as being unilaterally fixed or 
bilaterally pelvic sidewall fixed tumours. The patient’s treatment duration and 
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haemoglobin levels at the start of radiation were also retrieved from her medical 
records. Outcome was evaluated after six months, using the Papanicolaou smear 
and clinically, by using the Response Evaluation Criteria In Solid Tumors criteria 
version 1.1. Toxicity scoring was done by using the Radiation Therapy Oncology 
Group/Eastern Cooperative Oncology Group criteria. Maximum toxicity 
information during treatment and follow-up was obtained from patient files. 
Statistical analysis was done using STATISTICA version 10. The Student’s T-test 
was used for mean age and toxicity comparison between HIV positive and 
negative patients. Survival analysis was done using the Kaplan Meier statistical 
method. 
 
Results 
 
The 600 days overall survival and disease free survival were 94.92% and 59.04% 
respectively. Comparison of unilateral and bilateral pelvic sidewall fixed tumour 
disease free survival was 63.94% and 48% (p=0.12926) respectively. Seventy one 
(68.3%) patients were HIV negative while 33 (31.7%) were HIV positive. Human 
Immunodeficiency Virus positive patients had a mean age of 45.76 years, while 
the mean age for HIV negative patients were 55.95 years (p=0.000066). There 
was no statistically significant difference (p=0.49713) in disease free survival 
between patients completing radiation therapy in ≤24 days (57.03%) versus >24 
days (58.76%). There was no statistically significant difference in the outcomes 
between HIV positive and negative patients for the up to 600 day’s follow-up 
period. However, haemoglobin levels were prognostic, as the comparison between 
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patients with haemoglobin levels of ≤10g/dl and >10g/dl overall survival was 
80.05% and 98.81% (p=0.00055), and disease free survival was 0% and 68.57% 
(p=0.02130) respectively at 470 days. The treatment was well tolerated and there 
was no difference in toxicity between HIV positive and HIV negative patients. No 
patient developed acute grade 3-4 skin and genitourinary toxicity. One patient 
developed acute grade 3 gastrointestinal tract toxicity. Although the follow-up 
period was rather short to assess late complications, three patients who were HIV 
negative had late grade 3 skin toxicity, no patient had late genitourinary toxicity 
and four had late gastrointestinal tract toxicity. Among the four who had late 
gastrointestinal tract complications, three were HIV negative while one was HIV 
positive. 
 
Conclusion 
 
For this short follow-up study, the departmental hypofractionated protocol has 
potential and has already reduced long waiting periods for radiotherapy treatment 
in our department from six months to two to three months. The treatment is 
tolerable with a comparable outcome as conventional standard fractionation for 
stage 3b carcinoma of the cervix. However, long follow-up is recommended to 
ascertain long term outcome and late complications. As other studies have shown, 
carcinoma of the cervix is seen at an earlier age among HIV positive patients and 
screening is recommended. Interestingly, haemoglobin levels are prognostic 
among stage 3b carcinoma of the cervix, in patients treated with 
hypofractionation. 
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1. INTRODUCTION     
 
1.1 Background 
Cervical cancer is the third most common cancer in women, and the seventh 
overall, with an estimated 530 000 new cases being reported worldwide in 2008. 
More than 85% of the global burden occurs in developing countries where it 
accounts for 13% of all female cancers (7). 
 
In Africa, cervical cancer is the leading cancer among females and constitutes 
23.3% (14). 
 
Southern Africa is one of the high risk regions and the incidence is 26.8 per 100 
000 (7). 
 
Overall, the mortality: incidence ratio is 52%, and cervical cancer was responsible 
for 275 000 deaths in 2008, about 88% of which occurred in developing countries 
and 53 000 occurred in Africa (7). 
 
In South Africa, according to GLOBOCAN 2008, the incidence of cervix uteri 
cancer was 5 743 (7). 
 
At the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), we see on 
average, 750 new cases of cervical cancer patients every year and among them 
approximately 304 patients are stage 3b (12). According to Federation 
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International de Gynaecologic et Obestetrique (FIGO) staging, stage 3b cervical 
cancer means that the tumour extends to pelvic side walls and or causes hydro-
nephrosis or a non-functioning kidney (6). Patients with stage 3b as well as renal 
failure are evaluated differently.  
 
The waiting period was six months when these patients were treated with 
conventional fractionation, which is 2Gray (Gy) per fraction (12). In our 
department, stage 3b patients were treated with external beam radiation therapy of 
50Gy, plus three fractions of 8Gy intracavitary high dose rate brachytherapy, 
depending on the renal function and CD4 counts for retro positive patients, with 
concurrent cisplatinum chemotherapy of 80g/m
2
, three weekly (3). The reason for 
the long interval from assessment to planning of treatment is due to the burden of 
the disease compared to the resources available. 
 
With the majority of the carcinoma of the cervix being squamous cell carcinoma, 
one disadvantage of a long waiting period is that squamous carcinoma is a rapidly 
multiplying tumour with a potential doubling time (T-POT) of approximately 5 
days (17). Hence, from initial assessment to the time of simulation and treatment, 
most patients are upstaged, with a consequent poorer prognosis. 
 
In order to reduce the waiting period, our department adopted a new 
hypofractionated protocol for cancer of the cervix stage 3b, which comprises 
almost half the cases seen at the CMJAH. Waiting times improved and is 
currently 2-3 months (12). Hypofractionation means giving more than 2Gy per 
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fraction. The new protocol adopted, involves giving 2.5Gy per fraction of external 
beam radiation therapy to a total dose of 40Gy to the pelvis and intracavitary high 
dose rate brachytherapy of 9Gy weekly, to a total of 18Gy without chemotherapy. 
The treatment is given Monday to Friday (3). 
 
Hypofractionation involves giving a smaller number of larger doses per fraction. 
Treatment regimens involving fewer fractions, is clearly more convenient for 
patients and is of benefit in resource constraint health systems. Overall treatment 
time is important for fast growing tumours and as for carcinoma of the cervix, 
local tumour control is decreased by 0.5% each day that the overall treatment time 
is prolonged past 49 days (8).  
      
A recent study by Huang et al., (2012) (41), verifies the fact that accelerated 
repopulation does exist in cervical cancer and has a relatively short onset time. 
Higher dose and shorter treatment duration were associated with higher tumour 
control probability (TCP). According to his study the best TCP fit was achieved 
with an onset time (Tk) of acceleration of 19 days and a number of tumour 
clonogens(K) of 139 (41). This suggests that hypofractionation could be a 
potential choice of treatment for carcinoma of the cervix. 
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1.2 Chemotherapy and locally advanced carcinoma of the cervix 
 
Earlier studies showed chemotherapy survival benefit in stages1b-IV carcinoma 
of the cervix (45, 46 and 48). However, Vale et al., (2008) (49), showed in a 
systematic review and meta-analysis of individual patient data from 18 
randomised trials, that the benefit of chemotherapy decreases with stage 
progression. Indeed, stages 3 and 4 had a 5 year survival benefit of only 3% (49). 
Based on the above observation and the fact that most of our patients at CMJAH 
with locally advanced disease being unable to tolerate chemotherapy, patients 
with stage 3b on the departmental hypofractionated protocol do not receive 
concurrent chemotherapy. 
 
1.3 High dose rate brachytherapy of twice 9Gy each 
 
Studies by Patel et al., (1992) , Sood et al., (2002) and more recently from our 
department by Wondemagegnhu et al., (2007) have showed that two fractions of 
HDR brachytherapy of 9Gy each is safe and effective in the management of 
carcinoma of the cervix (50, 51 and 52). 
 
My study aimed to evaluate the outcome of this departmental hypofractionated 
protocol in terms of local control, early and late toxicity and also to compare HIV 
positive and negative patients with a mean follow-up of six months. I also 
compared the outcome for unilateral pelvic sidewall involvement to more 
advanced tumours. 
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1.4 SCIENTIFIC RATIONALE 
 
There are very few studies on the hypofractionation for cancer of the cervix. None 
of the studies was done in South Africa. This is a common cancer among the 
women in developing countries and with the rising HIV environment; the burden 
of cervical cancer might be even greater, stretching the limited resources even 
further. Thus, it is important to evaluate hypofractionated protocols and their 
potential. 
 
1.5 OBJECTIVES  
 
With respect to hypofractionated radiation for advanced cervical cancer, my study 
had four aims: 
1. To evaluate the early and late toxicity with a mean follow-up of six months. 
2. To asses local control after six months using Pap smear results post treatment. 
3. To compare local control and toxicity among HIV positive and negative 
patients. 
4. To compare outcomes of unilateral fixed to more advanced cervical tumours. 
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2. METHODOLOGY 
 
2.1 STUDY LOCATION 
 
The Radiation Oncology Department of the University of the Witwatersrand, 
South Africa based at the CMJAH. This is a tertiary referral hospital for the 
Southern Gauteng Province.  
 
2.2 STUDY SUBJECTS  
 
One hundred and four sequential patients treated with the departmental 
hypofractionated protocol between 2010 and 2011 were evaluated. 
 
2.3 STUDY DESIGN 
 
This was a retrospective descriptive study comprising two consecutive years.  
 
2.4 SAMPLE SIZE 
 
The specific number of patients (n=104) selected was due to: 
1) A study period of one year 
2) A particular disease stage investigated 
3) A particular schedule of a hypofractionated radiation protocol being assessed 
4) A minimum follow-up period of six months 
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2.5 STUDY SAMPLING METHOD 
 
Patients included were as follows: 
1) Local patients with contact telephone numbers, treated with the 
hypofractionated protocol 
2) The first 104 patients treated on this hypofractionated protocol were 
included in the study if they met the criterion described in point 1 above. 
 
2.6 STUDY PERIOD 
 
The total study period was two years: 2010-2011. 
 
2.7 INCLUSION CRITERIA  
 
- Squamous cell carcinoma histology of cervix only. 
-Stage 3b with normal renal function. 
-Hypofractionated protocol in previously untreated patient. 
-Both HIV positive and negative patients. 
-All ages. 
-Telephonically available for follow-up. 
 
2.8 EXCLUSION CRITERIA 
 
-No follow-up (no telephone). 
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2.9 STUDY MATERIALS 
 
A retrospective review of hospital records of patients treated with the 
hypofractionated protocol. The records analysed include: 
 Patient files 
 Laboratory records 
 Death certificates if applicable 
 
2.10 STUDY PROCEDURES 
 
2.10.1 Obtaining patient records  
The cancer of the cervix stage 3b cases that were treated with the hypofractionated 
protocol were identified through a review of records kept for each patient at our 
records office /statistics department. The hospital numbers were used to trace the 
patient case notes and laboratory data. 
 
2.10.2 Ascertainment/authentification of records  
To avoid missing patient files/records and to confirm authenticity of the said 
record, the principal investigator liaised with the records officers. Attempts were 
made to contact patient/family by phone if information was not in the file. Failing 
telephonic information, home affairs was contacted for a death certificate. 
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2.11 ETHICAL CONSIDERATIONS 
 
Ethical clearance was obtained from the University of the Witwatersrand Human 
Research Ethics Committee (Medical) with certificate number M110908 and 
permission of the CEO of the CMJAH was obtained before starting the study, as 
per university and hospital requirements.  
 
2.11.1 Study record confidentiality  
 
All data and materials extracted from the patients files/records was done with 
utmost respect and confidentiality. No patient identifiers was extracted or 
analyzed and all care taken into account to ensure that only the principal 
investigator had access to raw patient records through creation of a password 
protected Microsoft excel data flow sheet. The patient numbers used to extract the 
raw patient data into the excel sheets was not transcribed into the STATISTICA 
database for statistical analysis; instead each record packet was assigned a new 
study number. As such only the principal investigator was able to link the primary 
data with the secondary data. The data shall be used for the sole purpose of 
writing this dissertation and for scientific publications.  
 
2.12 Statistical analysis 
 
Statistical analysis was done using STATISTICA Version 10. Basic descriptive 
and frequency statistics of categorical and nominal data and comparisons using 
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the Students T-test was done. Survival statistical analysis using the Kaplan Meier 
statistical method was used to derive survival comparisons. A p value of less than 
0.05 was taken as significant. 
 
2.13 Toxicity analysis 
 
Toxicity was assessed based on RTOG/EORTC scoring system. See appendices B 
and C (5). 
 
2.14 Study variables 
 
The following data were reported for all case records reviewed: 
1. Demographic data including age and race. 
2. Haemoglobin levels at the start of radiation therapy. 
3. Human Immunodeficiency Virus status and whether on HAART at the 
start of radiation therapy. 
4. Histology. 
5. Stage 3b unilateral pelvic side wall invaded or more advanced disease. 
6. Kidney ultrasound findings at the start of radiotherapy whether 
hydronephrosis was present or not. 
7. Papanicolaou smear result 6 months post radiation therapy. 
8. Disease free survival and overall survival at 6 months. 
9. Radiation toxicity, for both early and late gastrointestinal, genitourinary, 
skin and mucosa. 
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2.15 Assessment record review during treatment and follow-up. 
 
Patients were followed according to departmental protocol for carcinoma of the 
cervix. Patients were reviewed once a week for toxicity during treatment, six 
weeks post treatment and then three monthly for the first year. Papanicolaou 
smears were done at six months post treatment. During follow-up, history and 
physical examination was done, including bimanual pelvic and rectal 
examinations. If required, imaging was done to confirm distant disease. 
 
2.16 Study data collection instruments 
 
All primary data extracted from raw patient records were entered into a Windows 
excel based data flow sheet. Data was cleaned up and verified, and all patient 
identifiers were removed prior to data being transcribed into a STATISTICA data 
base as secondary data ready for analysis using the STATISTICA software 
version 10. 
 
2.17 Study limitations  
 
This study was retrospective and unfortunately, some records were not kept well 
and therefore missing. 
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3. RESULTS  
Table 1 Patient characteristics  
Characteristic                                                                 Number of patients (%) 
Total number (n)            104 (100%) 
Age (y) 
            Mean                                                                 52.72 
            Range                                                                23-89 
Race (n) 
           Blacks                                                              102 (98.08) 
           White                                                                   1 (0.96) 
           Coloured                                                              1 (0.96) 
Haemoglobin at the start of RT 
Mean (g/dl)                                                         11.66 
Range (g/dl)                                                          7.5-15.2 
≤10g/dl (n)                                                          21(20.19) 
>10g/dl (n)                                                           83(78.81) 
Tumour extension to pelvic wall (n) 
Unilateral PSW                                                   53 (50.96) 
Bilateral PSW                                                     45 (43.27) 
No PSW                                                                6 (5.77) 
Hydronephrosis(n) 
No hydronephrosis                                             57 (54.81) 
       Unilateral                                                            32 (30.77) 
        Bilateral                                                              15 (14.42) 
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HAART status among HIV positive (n) 
On HAART                                                        14 (42.42) 
Not on HAART                                                  18 (54.55) 
Not known                                                            1 (3.03) 
Duration of treatment (days) 
Mean                                                                   25.97 
Range                                                                  21-54 
≤ 24 days (n)                                                       40 (38.46) 
>24 days (n)                                                        62 (59.66) 
Energy (n) 
Cobalt                                                                 16 (15.38) 
  6mv                                                                     49 (47.12) 
15mv                                                                   15 (14.42) 
18mv                                                                   21 (20.19) 
  Missing                                                                  3 (2.88) 
Technique (n) 
          AP/PA                                                                   99 (95.19) 
          Four field                                                                 5 (4.81) 
Pap smear results (n) 
Negative                                                            71 (68.3) 
Positive                                                                0 (0.00) 
Not done                                                             33 (31.7) 
PSW (pelvic side wall); AP/PA (anterior posterior/posterior anterior) 
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Table 2 Overall pattern of recurrence  
Failure site                                                                       Number of patients (%) 
No recurrence                                                                                 79 (75.96) 
Local only                                                                                       12 (11.5) 
Local + distant                                                                                  1 (0.96) 
Distant only                                                                                      2 (1.92) 
Not evaluable                                                                                  10(9.62) 
 
 
 
Table 3 Comparison of mean age between HIV negative and HIV positive 
patients  
 HIV NEGATIVE HIV POSITIVE 
MEAN AGE (YEARS) 55.95 45.76 
p=0.000066 
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Table 4 Clinical response after six months using a clinical assessment 
modelled on the RECIST criteria as explained in appendix D  
Response                                                                          Patients (%) 
Total number                                                                    104 (100) 
Complete                                                                            73 (70.19) 
Partial                                                                                  6 (5.77) 
Stable                                                                                   8 (7.69) 
Progressive                                                                           8 (7.69) 
Not evaluable                                                                       9 (8.65) 
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3.1 PATIENT AND DISEASE CHARACTERISTICS 
 
3.1.1 Age  
 
The mean age of the patients at the time of presentation was 52.72 years (range 
23-89 years). 
 
3.1.2 HIV status  
 
Seventy one (68.3%) patients were HIV negative while 33 (31.7%) were HIV 
positive. The mean age of HIV negative patients was 55.95 years while that of 
HIV positive patients was 45.76 years, which was statistically significant with a p 
value=0.000066. 
 
3.1.3 Race distribution  
One hundred and two patients (98.08%) were black, one patient (0.96%) was 
white and one (0.96%) was coloured. 
 
3.1.4 Haemoglobin levels  
The mean haemoglobin was 11.66g/dl (range 7.5-15.2 g/dl). Twenty one patients 
had haemoglobin levels of less or equal to 10g/dl and 83 patients had 
haemoglobin levels of more than 10g/dl. 
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3.1.5 Parametria tumour involvement  
Fifty three patients (50.96%) had unilateral pelvic side wall tumour involvement, 
forty five patients (43.27%) had more advanced tumours, extending to both pelvic 
side walls. Six patients (5.77%) had no tumour extension to the pelvic side walls 
and stage 3b based on having hydronephrosis. 
 
3.1.6 HAART status among HIV positive patients  
At the start of treatment only 14 patients (42.42%) were on HAART. Eighteen 
patients (54.55%) were not on HAART while one patient’s data was missing. 
 
3.1.7 Papanicolaou smear results after six months  
All the Pap smears that were done after six months among 71 patients (70.19%) 
were negative for intraepithelial malignancy. Two patients (1.92%) died post 
treatment before the six month follow-up, while 29 patient’s Pap smears were not 
done due to vaginal stenosis post radiation treatment. 
 
3.1.8 Duration of treatment  
The mean number of days of receiving treatment was 25.97 days (range 21 -54 
days). Forty (38.46%) patients (38.46%) completed radiation therapy on or before 
24 days while sixty two patients (59.66%) completed treatment after 24 days. 
Unfortunately two patient’s (1.92%) data was missing. 
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3.1.9 Overall pattern of recurrence  
Seventy nine patients (75.96%) had no local or distance recurrence of disease. 
Twelve patients (11.5%) had local recurrence, one (0.96) patient had both local 
and distance disease and two patients (1.92%) had only distant metastases. Ten 
patient’s (9.6%) data was missing. The local recurrences were mainly a mass in 
the vaginal wall, parametria and a tumour in the periurethral area. Distant 
metastases were mainly lung metastases, seen in two patients and one patient had 
both lung metastasis and a par-aortic mass.  
 
3.2 SURVIVAL RESULTS 
 
At six months after completion of radiation therapy 73 patients (70.19%) achieved 
a complete response, six patients (5.77%) had a partial  response, eight patients 
(7.69%) had no response (stable disease) and a further eight patients (7.69%) had 
progressive disease on follow-up. One patient died a few days post treatment 
while eight patient’s data were missing and hence not evaluable. 
 
 
 
 
3.2.1 Overall and disease free survival  
The 600 days cumulative overall survival after treatment completion was 94.92% 
as shown in Graph 1, while DFS over the same number of days was 59.04%, as 
shown in Graph 2. 
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Graph 1 Overall survival after treatment completion 
600 Days overall survival =94.92% 
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Graph 2 Disease free survival after treatment completion 
600 Days disease free survival=59.04% 
 
3.2.2 Disease free survival comparison between unilateral and bilateral pelvic 
sidewall fixed tumours  
Comparison of DFS between unilateral and bilateral pelvic side wall (PSW) 
involvement at 600 days was as follows: DFS for unilateral PSW 
involvement=63.94% and DFS for bilateral PSW involvement=48.79% (p =0.129)   
as seen in the Graph 3. 
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Graph 3 Disease free survival comparison between unilateral and bilateral 
pelvic sidewall tumour involvement 
 
Group 1 indicates the unilateral PSW involvement and Group 2 indicates the 
bilateral PSW involvement. 
 
3.2.3 Disease free survival comparison of HIV negative and HIV positive 
patients who were treated with radiotherapy  
In the DFS comparison between HIV negative and HIV positive radiation treated 
patients  at 600 days, the DFS for HIV negative patients was=55.13% and the 
DFS for HIV positive patients was=71.41%, with p=0.7229, as show in Graph 4. 
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Graph 4 Disease free survival comparison of HIV negative and HIV positive 
patients who were treated with radiotherapy 
 
3.2.4 Disease free survival comparison between patients with haemoglobin 
levels ≤10g/dl and >10 g/dl 
The DFS for patients with haemoglobin levels of more than 10g/dl  was 68.57%, 
while there was no patient with haemoglobin levels of less or equal  to 10 g/dl 
who survived after 470 days (p=0.0213), as shown in Graph 5. 
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Graph 5 Disease free survival comparison between patients with 
haemoglobin ≤10g/dl or >10g/dl 
 
3.2.5 Overall survival comparison between patients with haemoglobin levels 
≤10g/dl and >10g/dl 
Overall survival was 98.81% for patients with haemoglobin levels of more than 
10g/dl, while patients with haemoglobin levels of less or equal to 10g/dl had an 
OS=80.05% (p=0.00055), as show in Graph 6. 
 
24 
 
Cumulative Proportion Surviving (Kaplan-Meier)
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Graph 6 Overall survival comparison between patients with haemoglobin 
levels of ≤10g/dl or >10g/d 
 
3.2.6 Disease free survival comparison between patients who completed 
radiotherapy ≤24days and >24 days 
There was no statistical difference in the DFS between patients who completed 
treatment within 24 days and patients who were on radiotherapy for more than 24 
days, as indicated by Graph 7. 
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Graph7 Disease free survival comparison between patients who received 
radiation ≤24days and for >24 days 
The DFS for radiation treatment duration of ≤24 days =57.03% and similarly, the 
DFS for radiation treatment duration of >24 days =58.76%, with a p value of 
0.49713. 
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3.3 TOXICITY 
 
Table 5 Overall acute reactions 
ACUTE REACTIONS 
REACTION TOTAL GRADE 0 GRADE 1 GRADE 2 GRADE 3 GRADE 4 
SKIN 77 25 23 54 0 0 
GU 32 69 0 32 0 0 
GIT 39 61 2 36 1 0 
 
 
Table 6 Overall late reactions 
LATE REACTIONS 
REACTION TOTAL GRADE 0 GRADE 1 GRADE 2 GRADE 3 GRADE 4 
SKIN and/or 
VAGINA 
62 34 4 53 5 0 
GU 0 0 0 0 0 0 
GIT 5 91 0 1 4 0 
 
 
3.3.1 Acute skin reactions 
Seventy seven patients developed acute skin reactions. Twenty three patients had 
grade 1 and 54 patients had grade 2 acute skin complications. No patient 
developed acute grade 3 or 4 toxicity. Human Immunodeficiency Virus status did 
not have an effect on acute skin complications (See table 7). 
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Mean time=23.59 days 
Minimum=8 days 
Maximum=63 days 
 
Table 7 Acute skin reactions comparing HIV negative to HIV positive 
patients 
ACUTE SKIN 
TOXICITY 
HIV NEGATIVE HIV POSITIVE TOTAL 
GRADE 0 16 9 25 
GRADE 1 17 6 23 
GRADE 2 37 17 54 
GRADE 3 0 0 0 
GRADE 4 0 0 0 
TOTAL 70 32 102 
 
The mean time to acute skin reaction was 23.59days (Range 8-63 days). 
 
3.3.2 Acute genitourinary toxicity 
 
Thirty two patients developed acute grade 2 genitourinary reactions. No patient 
developed grade 1, 3, or 4 reactions. Patient’s HIV status did not affect acute 
genitourinary reaction (See table 8). 
Time to developing acute genitourinary toxicity: 
Mean time=19.03 days 
Minimum=2 days 
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Maximum=51 days 
 
Table 8 Acute genitourinary reactions comparing HIV negative to HIV 
positive patients 
ACUTE 
GENITOURINARY 
TOXICITY 
HIV NEGATIVE HIV POSITIVE TOTAL 
GRADE 0 43 26 69 
GRADE 1 0 0 0 
GRADE 2 26 6 32 
GRADE 3 0 0 0 
GRADE 4 0 0 0 
TOTAL 69 32 101 
 
The mean time to acute maximum genitourinary complication was 19.03 days 
(range2-51 days). All the patients who developed acute genitourinary toxicity had 
radiation induced cystitis and were treated with CITRO-SODA. 
 
3.3.3 Acute gastrointestinal toxicity 
 
Thirty nine patients developed acute gastrointestinal complications. Two patients 
had grade 1, 36 patients had grade 2 and 1 patient developed grade 3 
gastrointestinal toxicity. The patient who developed grade 3 toxicity had diarrhoea 
which required intravenous fluid. Human Immunodeficiency Virus status did not 
affect acute gastrointestinal complications (See table 9). 
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Time to developing acute gastrointestinal toxicity: 
Mean=15.5 days 
Minimum=1 day 
Maximum=27 days 
 
Table 9 Acute gastrointestinal reactions comparing HIV negative to HIV 
positive patients 
ACUTE 
GASTROINTESTINAL 
TOXICITY 
HIV NEGATIVE HIV POSITIVE TOTAL 
GRADE 0 44 17 61 
GRADE 1 2 0 2 
GRADE2 21 15 36 
GRADE3 1 0 1 
GRADE 4 0 0 0 
MISSING 1 0 1 
TOTAL 69 32 101 
 
The mean time to acute GIT complication was 15.5days (Range 1-27 days). 
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3.3.4 Late complications 
 
3.3.4.1 Late skin/vulvo-vaginal complications 
 
Sixty two patients developed late skin complications of which four had grade 1, 
53 had grade 2 and 5 had grade 3 toxicity. The patient’s HIV status did not affect 
late skin/vulvo-vagina complications. All the patients who developed grade 3 
toxicities had radiation proctitis (See table 10). 
Mean time=218.74 days 
Minimum=147 days 
Maximum=391days 
 
Table 10 Late skin/vulvo-vaginal reactions comparing HIV negative to HIV 
positive patients 
LATE SKIN TOXICITY HIV NEGATIVE HIV POSITIVE TOTAL 
GRADE O 25 9 34 
GRADE 1 3 1 4 
GRADE 2 34 19 53 
GRADE 3 5 0 5 
GRADE4 0 0 0 
TOTAL 67 29 96 
 
The patients’ late skin complications were assessed to a maximum follow-up of 
391 days. 
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3.3.4.2 Late genitourinary toxicity 
 
No patient developed late genitourinary complication up to a maximum follow-up 
of 390 days. 
 
3.3.4.3 Late gastrointestinal toxicity complications 
 
Five patients developed late GIT complications of which one had grade 2 and four 
had grade 3 toxicity. Patients’ late toxicity was assessed up to a maximum 278 
days. All the patients who had grade 3 toxicity had radiation induced proctitis 
which was confirmed by procto-sigmoidoscopy. The patients’HIV status did not 
affect late GIT complications (See table 11). 
Time to late gastrointestinal toxicity  
Mean time=241.75 days 
Minimum=202 days 
Maximum=278 days 
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Table 11 Late gastrointestinal toxicity reactions comparing HIV negative to 
HIV positive patients 
LATE GIT TOXICITY HIV NEGATIVE HIV POSITIVE TOTAL 
GRADE  0 64 27 91 
GRADE 1 0 0 0 
GRADE  2 0 1 1 
GRADE  3 3 1 4 
GRADE4 0 0 0 
TOTAL 67 29 96 
 
The mean time to late complication was 241 days (Range 202-278 days) 
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4. DISCUSSION 
 
4.1 Papanicolaou smear 
 
The use of Pap smears for cervical and vagina cytology as a follow-up study is 
controversial because of the bizarre post irradiation cellular morphology that 
renders it difficult to distinguish post irradiation changes from residual or 
recurrent malignant cells (20, 21). In my study, 73patients’ (70.19%) Pap smears 
were done six months post irradiation and all the results were cytologically 
negative for intraepithelial malignancy. Two patients died post treatment before 
six months and hence the Pap smear was not done. Twenty nine patients did not 
comply with post irradiation advice as to using a vaginal dilator and therefore on 
the sixth month visit, the vagina was stenosed and hence the Pap smear was not 
done. However, clinical assessment using speculum and per vaginal examination 
revealed different results from Pap smears. Using modified RECIST criteria (44), 
73% of the patients had a complete response, 6 had a partial response, and 8 had 
progressive disease while 9 patients were not evaluable at six months as one died 
while 8 had missing information. In asymptomatic patients, clinical assessment 
seemed to be a better tool of assessment than a Pap smear at six months. This 
could be due to a number of reasons including how the Pap smear was taken and 
the skills involved. Indeed, in a study done at the MD Anderson Cancer Centre on 
1 000 patients treated with either surgery or radiation therapy for stage 1B 
cervical cancer, post treatment Pap smears did not detect a single asymptomatic 
recurrence among 133 patients with recurrent disease (22). 
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4.2 Outcome and haemoglobin 
 
Many studies have demonstrated the prognostic significance of haemoglobin 
levels in terms of disease free survival and overall survival (23, 24, 25, 26, and 
27). In a review article of published data Vaupel et al., (28) concluded that 
maximum oxygenation of the tumour is expected with haemoglobin in the range 
of 12 to 14 g/dl for women and that higher levels of haemoglobin may not 
necessarily be better. In this study, I compared OS and DFS among patients with 
haemoglobin levels ≤10 and ≥ 10. The haemoglobin levels were measured at the 
start of radiotherapy. Patients with haemoglobin levels of more than 10g/dl had a 
98.8% OS while patients with haemoglobin equal or less than 10g/dl had an 80.05 
%OS, (p=0.00055). Disease free survival among patients with haemoglobin levels 
of more than 10g/dl was 68.57%, while no patient was disease free after 470 days 
with haemoglobin levels of less or equal to 10g/dl (p =0.02130). My study 
confirms and demonstrates the prognostic importance of haemoglobin levels in 
patients receiving radiotherapy. 
 
4.3 Human Immunodeficiency Virus status and outcome 
 
Campbell et al., (1999) (29) observed in his study on carcinoma of the cervix 
treated with radiation therapy, that HIV positive patients had more advanced 
tumours and that the duration of remission was shorter than in the HIV negative 
patients. Furthermore, women who are HIV positive also had a higher risk for 
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tumour recurrences after treatment and a higher risk of death as a consequence of 
the malignant process. 
In my study, there were 71 patients (68.3%) who were HIV negative and 33 
patients (31.7%) who were HIV positive. The mean age of HIV positive patients 
was 45.76 years, while the mean age for HIV negative women was 55.95 years 
(p=0.000066). Carcinoma of the cervix is seen at an earlier age among HIV 
positive patients as compared to in HIV negative patients in our department. 
There was no difference in DFS among the HIV positive (71.4%) and HIV 
negative (55.13%) patients, (p=0.72296). However, the duration of remission 
among HIV positive patients was shorter as compared to HIV negative patients. 
The HIV positive patients were disease free after 300days, while the HIV negative 
patients were disease free after 475 days. This concurs with Campbell’s study 
(29). 
 
4.4 Overall outcome 
 
Five year overall survival rates of 65-75%, 35-50% and 15-20% are reported for 
patients treated with radiotherapy alone for stage 2b, 3b, and 4 tumours 
respectively (30, 31, 32, 33). In other studies on stage 3b carcinoma of the cervix 
treated with conventional fractionation, the five year overall survival rates 
reported ranged from 25-48% and pelvic failure rates ranged from 38-50% (34, 
35). 
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A retrospective study by Muckasden et al,. (2002) (13) from the Tata Memorial 
Hospital in India reported that the five year DFS was 59% and the OS was 50% at 
a mean follow- up of 40 months.  Furthermore, a phase 1-2 study from Brazil by 
Viegas et al., (2004) reported that the three year OS was 76% and the five year 
OS was 59% (18). 
In my study, the OS for up to 600 days follow-up was 94.92% and the DFS was 
59.04%. The follow-up period was very short and longer follow-up is 
recommended. Despite the short follow-up, both the OS and the DFS compares 
well with conventional radiotherapy results found in the literature with a 
projection towards better survival. 
 
4.5 Impact of prolonged treatment time 
 
Several studies have described lower pelvic tumour control and survival rates in 
invasive carcinoma of the uterine cervix when the overall time in a course of 
irradiation is prolonged (36, 37, 38, and 39). Girinsky et al(38) in386 patients with 
stage 2b or 3 carcinoma of the cervix ,observed that the 10 year local recurrence 
free survival rate decreased when overall treatment time exceeded 52 days. A 
1.1% loss of pelvic tumour control per day was also observed in their regression 
analysis. Perez et al (40) also observed that there was a strong correlation between 
overall treatment time and survival. 
 
A recent study by Huang et al., (41) verifies the fact that accelerated repopulation 
does exist in cervical cancer and has a relatively short onset time. Higher dose and 
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shorter treatment duration were associated with higher TCP. They achieved the 
best fit with onset time Tk of 19 days. 
 
In this study, the patients were treated with a departmental hypo-fractionated 
protocol, in which the mean duration of treatment time was 25.97 days (range 21-
54 days).There was no difference in 600 days DFS (57.03% versus 58.76%, 
p=0.49713), and overall survival (97.43% versus 93.21%, p=0.38410) between 
patients who completed radiation therapy in less or equal to 24 days and more 
than 24 days as treatment times for the two groups were similar. Longer follow-up 
is required to ascertain the benefit of shorter treatment time. 
 
4.6 Outcome of unilateral versus bilateral pelvic sidewall tumours 
 
Patterns of care studies in stage 3a/3b patients indicate that survival is depended 
on the extent of the disease, with unilateral PSW involvement predicting a better 
outcome than bilateral involvement (42). Other studies have also correlated 
outcome with the tumour bulk, unilateral versus bilateral parametria or PSW 
involvement (32, 33). Souhami et al., (1987) (15) reported on the results of 
patients with stage 3b disease treated with radiation therapy alone. Patients with 
bilateral parametria disease involvement had a significantly lower survival than 
those with unilateral disease (43% versus 15%), (p=0.005). Lanciano et al., (1991) 
(43) also reported a significantly worse outcome in patients with bilateral 
parametria disease. 
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A Study by Arthur et al., in1995 (1) from Virginia, showed that stage 3b cancer of 
the cervix comprises of a heterogeneous group of diseases with different 
prognostic indices. They derived at a tumour burden scoring system by which 
FIGO stage 3b disease can be clinically divided into two prognostic groups. The 
five year local regional control was 62.9% and 40% for the low and high tumour 
burden groups respectively (1). 
 
A retrospective study by Hei-Yu et al., (2009) from Taiwan reporting on the 
aggressive characteristics of cervical cancer in young women also showed that 
parametria involvement is prognostic in early FIGO stage 1A-2A cervical cancer 
patients who underwent surgical procedure between Jan 1983 and Dec 2007.  
Parametrial involvement for stages 1A and 2A was 33.3% versus 12.0% 
respectively, (p=0.001) (9). My study shows a trend towards a better DFS after 
600 days follow-up in patients with unilateral as compared to bilateral PSW 
involvement (63.94% versus 48.79%), (p=0.12926). However, longer follow-up is 
recommended. 
 
4.7 Toxicity 
 
The incidence of major late sequelae of radiation therapy for stage 2b and 3 
carcinoma of the cervix is between 10%-15 % (53). However, a study by Bosset et 
al., (1997), reported the rate of late rectal morbidity was between 2-25% in 
radiotherapy patients (2). From a study by Swaroop et al., (1998), it appeared that 
the time of development of bleeding per rectum is between 6 months to one year 
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after completion of radiation therapy and is caused by friable mucosal 
angiogenesis (16). However, Yegappan et al., (1998) have reported a mean 
duration of 19.9 months for toxicity after radiotherapy for development of 
bleeding per rectum (19). According to studies reported in the literature, late 
urinary tract complications are seen frequently 3- 5 years after treatment (19, 57, 
58). Radiation cystitis is observed in 6-15% of patients receiving pelvic 
radiotherapy (10, 11, 4). Pedersen et al., (1994) (54) recommended that actuarial 
estimates rather than frequency of sequelae be reported. Montana et al.,(1986) 
(35), Perez et al.,(1999) (55) and Pourguier et al., (1982) (56) have noted that the 
incidence of radiation complications depended on the dose delivered. 
Hypo-fractionated studies for carcinoma of the cervix by Muckasden et al., (2000) 
(13) and Viegas et al., (2004) (18) showed comparable sequelae as conventional 
radiation therapy. Although, in the study by Viegas et al., (2004) (18) concurrent 
chemo-radiation was given at 2.5Gy twice daily to a total of 40Gy plus 35Gy Low 
Dose Rate brachytherapy delivered to point A. Chemotherapy consisted of 
15mg/m
2
 Cisplatin and 400mg/m
2
 5-Fluorouracil intravenous infusion. The study 
by Muckasden et al., (2000) (13) used standard pelvic portals to a total dose of 
39GyEBRT in 13 fractions plus intra-cavity brachytherapy. 
 
In my study, there was no patient with acute grade 3 or 4 skin and/or GU 
complications. Only one patient had acute grade 3 GIT toxicity. The patient had 
diarrhoea which required admission and intravenous fluid support.  
Five patients who were also HIV negative, developed late grade 3 skin 
complications. There was no patient with late bladder complications up to a 
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maximum follow-up of 390 days. Four patients had late grade 3 GIT 
complications. Among them one patient was HIV positive while three were HIV 
negative. All of these patients had radiation induced proctitis based on procto 
sigmoidoscopy and were treated with formalin injection and sucralfate enemas. 
The earliest radiation proctitis was seen after 202 days. 
 
The difference in toxicity between HIV positive and HIV negative patients was 
not statistically significant. 
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5. CONCLUSIONS 
 
Given the limitations of this study, viz, retrospective study, short observation time 
(600days) and the crude assessment by clinical examination, these preliminary 
outcomes are promising. A DFS of 59% and a low severe complication rate 
compares favourably with conventionally treated patients with stage 3 cervical 
cancer.  The protocol is resource sparing (reduced long waiting for radiotherapy in 
our department from 6 months to 2-3 months) and if long term results are 
satisfactory, the protocol may be recommended for use in resource constrained 
departments. The reduced overall treatment time may confer an advantage in 
reducing tumour re-population during treatment.  
 As other studies have shown, carcinoma of the cervix is seen at an earlier age 
among HIV positive patients and screening of HIV positive women for cervical 
cancer is recommended. Furthermore, haemoglobin levels are also found to be 
prognostic among stage 3b cervical carcinoma patients treated with 
hypofractionation, as it is in patients treated with conventional fractionation. 
Importantly, monitoring and correction of anaemia is highly recommended. 
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APPENDIX A 
FIGO staging of carcinoma of uterine cervix 
I Cervical cancer confined to the uterus (extension to corpus should be disregarded). 
IA Pre–clinical invasive carcinoma, diagnosed by microscopy only. 
IA1 measured stromal invasion < 3 mm in depth and < 7 mm in horizontal spread. 
IA2 measured stromal invasion > 3 mm and not > 5 mm with horizontal spread of < 7 
mm. 
IB clinically visible lesion confined to the cervix or microscopic lesion > IA2. 
IB1 clinically visible lesion < 4 cm in greatest dimension. 
IB2 clinically visible lesion > 4 mm in greatest dimension. 
II cervical carcinoma invades beyond uterus, but not to the pelvic wall or to the lower 
third of vagina. 
IIA Tumour without parametrial invasion. 
IIB Tumour with parametrial invasion. 
III Tumour extends to pelvic wall, and/or involves the lower third of vagina, and/or causes  
hydronephrosis or non-functioning kidney. 
IIIA Tumour involves lower third of vagina, no extension to pelvic wall. 
IIIB Tumour extends to pelvic wall and/ or causes hyderonephrosis or non-functioning  
Kidney 
IVA Tumour invades mucosa of bladder or rectum and/or extends beyond the true pelvis. 
IVB Distant metastasis 
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APPENDIX B–  RTOG acute radiation morbidity scoring criteria 
 
 
 
Organ 
Tissue 
[0] [1] [2] [3] 
[4] 
Skin 
No change 
over 
baseline 
Follicular, faint or dull 
erythema/epilation/dry 
desquamation/decreased 
sweating 
Tender or bright erythema, 
patchy moist 
desquamation/moderate 
edema 
Confluent, moist 
desquamation other 
than skin folds, 
pitting edema 
Ulceration, 
hemorrhage, 
necrosis 
Mucous 
membrane 
No change 
over 
baseline 
Injection/may 
experience mild pain 
not requiring analgesic 
Patchy mucositis that may 
produce an inflammatory 
serosanguinous 
discharge/may experience 
moderate pain requiring 
analgesia. 
Confluent 
fibrinousmucositis 
/may include severe 
pain requiring 
narcotic 
Ulceration, 
hemorrhage or 
necrosis 
Lower G.I 
including 
pelvis 
No change 
Increased frequency or 
change in quality of 
bowel habits not 
requiring medication/ 
rectal discomfort not 
requiring analgesics 
Diarrhoea requiring 
parasympatholytic drugs ( 
e.g. Lomotil)/mucous 
discharge not necessitating 
sanitary pads/rectal or 
abdominal pain requiring 
analgesics 
Diarrhoea requiring 
parenteral 
support/severe 
mucous or blood 
discharge 
necessitating sanitary 
pads/abdominal 
distention (flat plate 
radiograph 
demonstrates 
distended bowel 
loops) 
Acute or subactue 
obstruction, 
fistula or 
perforation; GI 
bleeding 
requiring 
transfusion; 
abdominal pain 
or tenesmus 
requiring tube 
decompression or 
bowel diversion 
Genitourina
ry 
No change 
Frequency of urination 
or nocturia twice 
pretreatment 
habit/dysuria, urgency 
not requiring 
medication. 
Frequency of urination or 
nocturia that is less 
frequent than every hour. 
Dysuria, urgency, bladder 
spasm, requiring local 
anesthetic (e.g. Pyridium) 
Frequency with 
urgency and nocturia 
hourly or more 
frequently/dysuria, 
pelvis pain or 
bladder spasm 
requiring regular, 
frequent 
narcotic/gross 
hematuria 
with/without clot 
passage 
Hematuria 
requiring 
transfusion/acute 
bladder 
obstruction not 
secondary to clot 
passage, 
ulceration or 
necrosis 
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APPENDIXC - RTOG/EORTC late radiation morbidity scoring scheme 
Organ 
Tissue 
0 Grade 1 Grade 2 Grade 3 Grade 4 5 
Skin None 
Slight atrophy; 
pigmentation 
change; some 
hair loss 
Patch atrophy; 
moderate 
telangiectasia; 
total hair loss 
Market atrophy; 
gross 
telangiectasia 
Ulceration  
Mucous 
membrane 
None 
Slight atrophy 
and dryness 
Moderate 
atrophy and 
telangiectasia; 
little mucous 
Marked atrophy 
with complete 
dryness. Severe 
telangiectasia 
Ulceration 
Death directly 
related to 
radiation late 
effects 
Small/Larg
e intestine 
None 
Mild diarrhea, 
mild cramping; 
bowel 
movement 5 
times daily, 
slight rectal 
discharge or 
bleeding 
Moderate 
diarrhea and 
colic; bowel 
movement >5 
times daily; 
excessive rectal 
mucous or 
intermittent 
bleeding 
Obstruction or 
bleeding, 
requiring 
surgery 
Necrosis/ 
Perforation 
Fistula 
Death directly 
related to 
radiation late 
effects. 
Bladder None 
Slight epithelial 
atrophy; minor 
telangiectasia ( 
microscopic 
hematuria) 
Moderate 
frequency; 
generalized 
telangiectasia; 
intermittent 
macroscopic 
hematuria 
Severe 
frequency & 
dysuria; severe 
generalized 
telangiectasia ( 
often with 
petechiae); 
frequent 
hematuria; 
reduction in 
bladder capacity 
(,150cc) 
Necrosis/Contract
ed bladder 
(capacity<100cc) 
Severe 
hemorrhagic 
cystitis 
Death directly 
related to 
radiation late 
effects. 
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Appendix D 
4.3. Clinical response after six months using clinical assessment modelled on recist criteria explained 
here. 
4.3.1. Evaluation of target lesions  
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph  
nodes (whether target or non-target) must have reduction in short axis to<10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions,  
taking as reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the  
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is  
also considered progression). 
Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to  
qualify for PD, taking as reference the smallest sum diameters while on study. 
 
 
